Table 4.
Clinical results of studies using different isodose prescription
Author/publication year | n | PIL | Operable | Tumor size | Dose | 3 Year LCa | 3 YearOSa | Grade ≥2 pulmonary toxicity |
---|---|---|---|---|---|---|---|---|
<3/≥ 3 cm | (in 5 fractions) | |||||||
Takeda et al. [2] 2009 | 63 | 80% | 14 (22%) | 38/25 | 50 Gy | 93% | 73% | 5% |
Tsurugai et al. [3] 2019 | 250b | 60% | 66 (28%) | 160/90 | 60 Gy (n = 66) | 99% | 78% | 9.6% |
50 Gy (n = 157) | ||||||||
40 Gy (n = 27) |
aLC = Local control, OS = overall survival.
b250 Tumors in 237 patients.